Source: Health Sciences Authority (SG) Revision Year: 2022 Publisher: Abbott Products Operations AG, Hegenheimermattweg 127, 4123 Allschwil, Switzerland
Hypercholesterolaemia and hypertriglyceridaemia alone or combined (type IIa, IIb, III, IV and V dyslipidaemias) in patients unresponsive to dietary and other non-drug therapeutic measures (e.g. weight reduction or increased physical activity), particularly when there is evidence of associated risk factors such as hypertension and smoking.
The treatment of secondary hyperlipoproteinaemia is indicated if the hyperlipoproteinaemia persists despite effective treatment of the underlying disease (e.g.dyslipidaemia in diabetes mellitus).
Dietary measures initiated before therapy should be continued.
LIPANTHYL PENTA 145 is indicated for the reduction in the progression of diabetic retinopathy in patients with type 2 diabetes and existing diabetic retinopathy. Lipanthyl does not replace the appropriate control of blood pressure, blood glucose and blood lipids in reducing the progression of diabetic retinopathy.
The recommended dose is one tablet containing 145 mg fenofibrate taken once daily. Patients currently taking one 200mg capsule or one 160mg tablet can be changed to one 145 mg fenofibrate tablet without further dose adjustment.
For hyperlipidaemia indications, response to therapy should be monitored by determination of serum lipid values. If an adequate response has not been achieved after several months (e.g. 3 months), complementary or different therapeutic measures should be considered.
If a patient needs fenofibrate for both hyperlipidemia and diabetic retinopathy indications, only one tablet of fenofibrate 145 mg per day should be taken.
Geriatric patients: In elderly patients, without renal impairment, the usual adult dose is recommended.
Renal impairment: Dosage reduction is required in patients with renal impairment.
In moderate chronic kidney disease (creatinine clearance 30 to 59 mL/min), and if a low dose is available, start with one capsule of 100 mg standard or 67 mg micronized once daily.
If no low dose is available, then fenofibrate is not recommended.
In patients with severe chronic kidney disease (creatinine clearance <30ml/min), LIPANTHYL PENTA 145 is contraindicated.
Hepatic impairment: LIPANTHYL PENTA 145 is not recommended for use in patients with hepatic impairment due to the lack of data.
Pediatric population: The safety and efficacy of fenofibrate in children and adolescents younger than 18 years has not been established. No data are available. Therefore, the use of fenofibrate is not recommended in paediatric subjects under 18 years.
LIPANTHYL PENTA 145, Film-coated tablet may be given at any time of the day, with or without food (see section 5.2 Pharmacokinetic properties). Tablet should be swallowed whole with a glass of water.
Only anecdotal cases of fenofibrate overdosage have been received. In the majority of cases no overdose symptoms were reported.
No specific antidote is known. If an overdose is suspected, treat symptomatically and institute appropriate supportive measures as required. Fenofibrate cannot be eliminated by haemodialysis.
Please refer to the product carton for expiry.
Store in the original package in order to protect from light and moisture, at a temperature not exceeding 30°C.
Thermoformed blister strips (clear PVC/PE/PVDC sealed with aluminium complex).
Boxes of 30 tablets.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
